At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 20 enrolled
Drug / intervention
Anakinra +1 moredrug
Likely dose
Sodium Chloride 9mg/ml Injectionfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis: A Randomized Controlled Trial With Anakinra vs. Placebo
In Brief
A Phase 3 clinical trial evaluating Anakinra and Sodium Chloride 9mg/ml Injection for Allergic Contact Dermatitis. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The study will investigate if Anakinra can ameliorate allergic contact dermatitis in participants with known nickel allergy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Contact Dermatitis
CountriesDenmark
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedAug 2022
Enrollment StartOct 2022
Primary CompletionDec 2023
Study CompletionAug 2024
TodayJul 2026
First PostedAug 12, 2022
Enrollment StartOct 11, 2022
Primary CompletionDec 1, 2023
Study CompletionAug 1, 2024
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 3.9 years ago
Interventions
Anakinradrug
100 mg Anakinra injections s.c.
Sodium Chloride 9mg/ml Injectiondrug
9 mg Sodium Chloride injections s.c.